EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Neoleukin Therapeutics's enterprise value is $-35.02 Mil.
Neoleukin Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, Neoleukin Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Neoleukin Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 11 years, the highest EV-to-Revenue of Neoleukin Therapeutics was 13.00. The lowest was -2.55. And the median was -0.49.
NLTX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.63 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neoleukin Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Neoleukin Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neoleukin Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Neoleukin Therapeutics's EV-to-Revenue falls into.
Neoleukin Therapeutics's current Enterprise Value is $-35.02 Mil.
Neoleukin Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neoleukin Therapeutics's share price for today is $3.49.
Neoleukin Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neoleukin Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Neoleukin Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NLTX has been successfully added to your 